Indeed, treatment with broad purinoceptor antagonists has shown some impact in the mdx model of DMD (reviewed in [13]), as did our short-term administration of P2RX7 antagonists (Fig 12). The gene discussed is P2RX7; the disease is Duchenne muscular dystrophy.